Abstract
Abstract Calusterone, 200 mg daily by mouth, significantly raised platelet counts of 80 women with advanced breast cancer. It showed no erythropoietic activity. Simultaneous measurements in 27 patients receiving Δ1-testoloactone, 1000 mg a day, were not significantly different from those of 21 untreated patients. Calusterone is clinically well tolerated, is weakly androgenic, and, like other 17-alpha alkylated steroids, causes bromsulphalein retention but no hepatocellular damage or jaundice. Its thrombocytopoietic effect in women with advanced breast cancer warrants investigation in patients with thrombocytopenic purpura or aplastic anemia and in patients undergoing chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
